Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival-Reference-Cited by-同舟云学术

Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival

Published:2015-01 Issue:1 Volume:136 Page:121-129
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Tate Thigpen J.

Funder

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference70 articles.

1. Cancer Facts & Figures, 2013;American Cancer Society,2013

2. Ten-year relative survival for epithelial ovarian cancer;Baldwin;Obstet Gynecol,2012

3. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer;van der Burg;N Engl J Med,1995

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chauhan Weighted Trajectory Analysis Reduces Sample Size Requirements and Expedites Time-to-Efficacy Signals in Advanced Cancer Clinical Trials;BioMedInformatics;2024-07-11

2. Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study;Cancer Imaging;2023-06-15

3. Label-Free Quantification Mass Spectrometry Identifies Protein Markers of Chemotherapy Response in High-Grade Serous Ovarian Cancer;Cancers;2023-04-06

4. Early onset neutropenia: a useful predictor of chemosensitivity and favorable prognosis in patients with serous ovarian cancer;BMC Cancer;2020-02-12

5. Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab;Clinical Medicine Insights: Oncology;2019-01